### Edgar Filing: SUVARI TRICIA BORGA - Form 5

### SUVARI TRICIA BORGA

Form 5

February 14, 2019

<b>FORM</b>	15								OMB AF	PROVAL			
·		STATES					GE CC	MMISSION	OMB Number:	3235-0362			
Check this box if no longer subject			Washington, D.C. 20549						Expires:	January 31,			
to Section Form 4 or 5 obligati may cont See Instru 1(b).	n 16. r Form ANI ons inue. action	ATEMENT OF CHANGES IN BENEFICIAL DWNERSHIP OF SECURITIES  ection 16(a) of the Securities Exchange Act of 1934,					Estimated average burden hours per response 1.0						
	Toldings Section 17	(a) of the l	Public U		g Compa	any A	Act of 1	935 or Section	1				
SUVARI TRICIA BORGA Symbo				ol Pool Therapeutics, Inc.				5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)					
(Last)	(Mo								Director 10% Owner _X Officer (give title Other (specify below) Chief Legal Officer				
THERAPE	AL BLOOD UTICS, INC., 1 POINT BLVD., S							Cnie	i Legai Officer				
					endment, Date Original 6 onth/Day/Year)				6. Individual or Joint/Group Reporting  (check applicable line)				
SOUTH SA FRANCISO	AN CO, CA 9408	0					_	X_Form Filed by 0 Form Filed by M 'erson					
(City)	(State)	(Zip)	Tab	le I - Non-Der	ivative Sec	curitio	es Acqui	red, Disposed of	, or Beneficial	y Owned			
1.Title of Security (Instr. 3)	2. Transaction Dat (Month/Day/Year)		n Date, if	3. Transaction Code (Instr. 8)	4. Securit (A) or Di (Instr. 3,	spose 4 and (A) or	d of (D)	5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Common Stock	07/31/2018	Â		A4	419 (1)	A	\$ 35.53	10,704	D	Â			
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.				Persons wi	SEC 2270 (9-02)								

the form displays a currently valid OMB control number.

#### Edgar Filing: SUVARI TRICIA BORGA - Form 5

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	cisable and	7. Titl	e and	8. Price of
	Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction	Number	Expiration D	ate	Amou	int of	Derivative
	Security	or Exercise		any	Code	of	(Month/Day/	Year)	Under	lying	Security
(Instr. 3) Price of Derivative		Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Secur	ities	(Instr. 5)
		Derivative				Securities			(Instr. 3 and 4		
		Security				Acquired					
						(A) or					
						Disposed					
						of (D)					
						(Instr. 3,					
						4, and 5)					
										Amount	
						Date Exercisable	Expiration Date	Title 1	or		
									Number		
									of		
					(A) (D)				Shares		

## **Reporting Owners**

Reporting Owner Name / Address

Director 10% Owner Officer Other

SUVARI TRICIA BORGA

C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO, CAÂ 94080

 $\hat{A}$   $\hat{A}$   $\hat{A}$  Chief Legal Officer  $\hat{A}$ 

of D

## **Signatures**

/s/ Lesley Ann Calhoun, as
Attorney-in-Fact
02/14/2019

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2